502767-45-5

Usage

Chemical structure

A 1,3,5-triazine ring with an attached amine group and a 4,6-dichloro-N-(3-fluoro-4-methoxyphenyl) side chain.

Derivative

It is a derivative of triazine, a class of organic compounds with a six-membered ring containing four nitrogen atoms.

Halogen atoms

Contains both chlorine and fluorine atoms in its structure.

Functional groups

The presence of an amine group (-NH2) and a methoxy group (-OCH3) in the molecule.

Potential applications

May have applications in pharmaceuticals, agrochemicals, or materials science due to its unique structure and potential reactivity.

Further research

More research is needed to fully understand its properties and potential uses.

Reactivity

The presence of halogen atoms and the amine group may contribute to the compound's reactivity, making it a candidate for various chemical reactions and applications.

Molecular weight

The molecular weight of the compound is approximately 276.12 g/mol.

Solubility

The compound's solubility in various solvents is not provided in the material, but it may be influenced by the presence of polar functional groups and halogen atoms.

Upstream product

• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 366-99-4 3-fluoro-4-methoxyaniline 

Downstream Products

• 502767-46-6 6-chloro-N₂-cyclohexylmethyl-N₄-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine 
• 676360-62-6 6-chloro-N₂-cyclopropyl-N₄-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine 
• 502767-47-7 6-chloro-N₂-cycloheptyl-N₄-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine 
• 502767-69-3 N,N'-dicyclopropyl-N-(3-fluoro-4-methoxy-phenyl)-1,3,5-triazine-2,4,6-triamine 
• 502766-82-7 N₂-[(1-ethyl-2-pyrrolidinyl)methyl]-N₄-(3-fluoro-4-methoxyphenyl)-6-[(S)-2-(methoxymethyl)-1-pyrrolidinyl]-1,3,5-triazine-2,4-diamine 
• 502766-72-5 N₂-ethyl-N₄-[(1-ethyl-2-pyrrolidinyl)methyl]-N₆-(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine 
• 502767-68-2 N,N'-di-n-propyl-N-(3-fluoro-4-metlioxy-phenyl)-1,3,5-triazine-2,4,6-triamine 
• 676360-72-8 6-chloro-N₂,N₄-bis-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4-diamine 

Relevant academic research and scientific papers

Triazine compounds and their analogs, compositions, and methods

The present invention relates to triazine compounds and their analogs and derivatives, and methods and compositions comprising these compounds. The compounds and compositions of this invention are useful for, among other things, treating pathophysiological conditions arising from inflammatory responses, inhibiting or blocking glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells, inhibiting smooth muscle proliferation, treating vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis, and the like.

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.